BMO Capital Starts Ascendis Pharma (ASND) at Outperform

August 18, 2026 4:13 PM

BMO Capital analyst David Lebowitz initiates coverage on Ascendis Pharma (NASDAQ: ASND) with a Outperform rating, PT $319.00.The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found